Vinblastine
Vinblastine is a pharmaceutical drug with 87 clinical trials. Currently 23 active trials ongoing. Historical success rate of 77.2%.
Success Metrics
Based on 44 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
49
Mid Stage
24
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
75.9%
44 of 58 finished
24.1%
14 ended early
23
trials recruiting
87
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Clinical Trials (87)
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 87